June 30, 2025 02:51 PM EDT

Arcturus claims Phase 2 success in first data since shift to mRNA therapeutics, investor reaction is muted

Max Gelman

Senior Editor

Arcturus said a Phase 2 mRNA therapeutic program achieved its goals in a rare disease population, though the results are early and Wall Street appeared …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Arcturus claims Phase 2 success in first data since shift to mRNA therapeutics, investor reaction is muted

Max Gelman

Senior Editor

Sign up to read this article for free.

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

Supreme Court passes on Oklahoma’s drug middlemen spat

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Sage plans to lay off almost every employee after inking Supernus deal

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Arc­turus claims Phase 2 suc­cess in first da­ta since shift to mR­NA ther­a­peu­tics, in­vestor re­ac­tion is mut­ed

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Ap­ple Tree Part­ner­s' biotechs 'face im­mi­nent col­lapse' as firm bat­tles Russ­ian in­vestor in court

Supreme Court pass­es on Ok­la­homa’s drug mid­dle­men spat

Ab­b­Vie bags Cap­stan’s in vi­vo CAR-T work with $2.1B buy­out deal

Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Arcturus claims Phase 2 success in first data since shift to mRNA therapeutics, investor reaction is muted

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

Supreme Court passes on Oklahoma’s drug middlemen spat

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Sage plans to lay off almost every employee after inking Supernus deal

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'